Allos Therapeutics Appoints Marc Graboyes as Vice President, General Counsel

Allos Therapeutics Appoints Marc Graboyes as Vice President,
General Counsel 


WESTMINSTER, Colo., Oct. 13  /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc.
(NASDAQ:ALTH) today announced the appointment of Marc Graboyes as Vice
President, General Counsel, effective October 11, 2004.  Mr. Graboyes was most
recently with Cooley Godward LLP, where he was a senior associate in the firm's
Business department and served as outside legal counsel to Allos for nearly
five years.  He will report directly to the Company's President and Chief
Executive Officer, Michael E. Hart, and will serve as a member of Allos'
Management Team.

"We're excited to welcome Marc to Allos," said Michael E. Hart, President and
Chief Executive Officer of Allos.  "As a longtime advisor to the Company, Marc
has an intimate understanding of the issues facing our business and industry. 
We expect he will play a significant role in helping to shape our future
strategic direction."

Mr. Graboyes brings over eight years of experience in counseling public and
private technology companies in all aspects of their formation and development.
 During his tenure at Cooley Godward, he developed extensive expertise in
public and private financings, mergers and acquisitions, corporate governance
and securities law disclosure and compliance matters. Prior to joining Cooley
Godward, Mr. Graboyes served as a business associate at several other national
firms, including Perkins Coie LLP, LeBoeuf, Lamb Greene & MacRae LLP and Arnold
& Porter LLP.  Mr. Graboyes earned his law degree from the University of
Colorado School of Law, where he graduated in the top 10% of his class and was
a member of the law review.  He also received his B.S. in Entrepreneurship &
Small Business Management from the University of Colorado at Boulder.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing
and commercializing innovative drugs for improving cancer treatments.  The
company's lead clinical candidate, EFAPROXYN(TM), is a synthetic small molecule
that has the potential to sensitize hypoxic (oxygen deprived) tumor tissues and
enhance the efficacy of standard radiation therapy.  In addition, Allos is
developing PDX (pralatrexate), a novel small molecule cytoxic injectable
antifolate (DHFR inhibitor) intended to treat non- small cell lung cancer,
mesothelioma and non-Hodgkin's lymphoma.  For more information, please visit
the company's web site at: http://www.allos.com/. 

DATASOURCE: Allos Therapeutics, Inc.



CONTACT:  Jennifer Neiman, Manager, Corporate Communications of Allos

Therapeutics, [phone], 



Web site:  http://www.allos.com/ 

Copyright